Skip to contentN
Nika Pharmaceuticals, Inc
N
NIKANika Pharmaceuticals, Inc Q1 2026 · 10-Q
Revenue—
Net Income-$13.36K-$13.36KN/M vs Q1 2025 EPS Diluted$0.00$0.00— vs Q1 2025 Operating Income-$13,359N/M Operating Cash Flow-$13,359N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nika Pharmaceuticals, Inc · CIK 1145604 · Engraved from SEC EDGAR
ended Mar 31, 2026 · filed May 12, 2026 · 42 d after period end